Benzinga · Apr 7, 2026
Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $24
Citigroup analyst Patrick Donnelly maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $18 to $24.
TX
NASDAQ · TXG
10x Genomics, Inc.
Healthcare · Medical - Healthcare Information Services
$90.36
Up+$0.54 (+0.60%)
Updated Oct 1, 2026, 3:13 PM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.04B
- P/E ratio
- -27.21
- Dividend yield
- 0.00%
- 52-week range
- $15.90 – $95.16
- Volume
- 3.75M
- Avg. volume
- 2.84M
Price performance · TXG
TXG price history
1M range · 0 trading sessions · Daily adjusted prices
TXG does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest TXG news
The latest Smart Investors Daily articles mentioning TXG.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TXG research
Overview
Company profile and research snapshot.
Company profile
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $15.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | Leerink Partners | Market Perform | — |
| Sep 28, 2026 | Piper Sandler | Neutral | — |
| Sep 28, 2026 | Argus Research | Buy | — |
| Sep 9, 2026 | UBS | Neutral | — |
| Sep 1, 2026 | RBC Capital | Sector Perform | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 31, 2026
William Blair Upgrades 10x Genomics to Outperform
William Blair analyst Matt Larew upgrades 10x Genomics (NASDAQ:TXG) from Market Perform to Outperform.
Benzinga · Mar 31, 2026
10x Genomics Seen As Key Player In AI-Driven Biological Data Buildout
William Blair upgrades 10x Genomics, citing AI-driven data demand, improving execution and Xenium validation as key growth drivers.
Benzinga · Mar 2, 2026
Breaking Down 10x Genomics: 11 Analysts Share Their Views
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
